Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126182961 | 12618296 | 1 | I | 20160213 | 20160726 | 20160803 | 20160803 | EXP | PHHY2016FR104312 | NOVARTIS | 65.43 | YR | F | Y | 59.50000 | KG | 20160803 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126182961 | 12618296 | 1 | PS | NEORAL | CYCLOSPORINE | 1 | Oral | UNK | 50715 | ||||||||||
| 126182961 | 12618296 | 2 | SS | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | 1.75 G, BID | Y | 0 | 1.75 | G | BID | ||||||
| 126182961 | 12618296 | 3 | SS | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | 500 MG, BID | Y | 0 | 500 | MG | BID | ||||||
| 126182961 | 12618296 | 4 | SS | ROVALCYTE | VALGANCICLOVIR HYDROCHLORIDE | 1 | Oral | 1 DF, FOUR DAYS A WEEK | 0 | 1 | DF | FILM-COATED TABLET | |||||||
| 126182961 | 12618296 | 5 | C | SOLUPRED | PREDNISOLONE | 1 | Oral | 10 MG, QD | U | 0 | 10 | MG | TABLET | QD | |||||
| 126182961 | 12618296 | 6 | C | KEPPRA | LEVETIRACETAM | 1 | Oral | 500 MG, BID | U | 0 | 500 | MG | TABLET | BID | |||||
| 126182961 | 12618296 | 7 | C | LEVOTHYROX | LEVOTHYROXINE | 1 | Oral | 50 UG, QD | U | 0 | 50 | UG | QD | ||||||
| 126182961 | 12618296 | 8 | C | URBANYL | CLOBAZAM | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | QD | ||||||
| 126182961 | 12618296 | 9 | C | MIRCERA | METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA | 1 | Intravenous (not otherwise specified) | 100 UG, QMO | U | 0 | 100 | UG | /month | ||||||
| 126182961 | 12618296 | 10 | C | LASILIX | FUROSEMIDE | 1 | Oral | 250 MG, BID | U | 0 | 250 | MG | BID | ||||||
| 126182961 | 12618296 | 11 | C | HEPARIN | HEPARIN SODIUM | 1 | Intravenous (not otherwise specified) | 8000 IU, QD | U | 0 | 8000 | IU | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126182961 | 12618296 | 1 | Product used for unknown indication |
| 126182961 | 12618296 | 2 | Product used for unknown indication |
| 126182961 | 12618296 | 4 | Product used for unknown indication |
| 126182961 | 12618296 | 5 | Product used for unknown indication |
| 126182961 | 12618296 | 6 | Product used for unknown indication |
| 126182961 | 12618296 | 7 | Product used for unknown indication |
| 126182961 | 12618296 | 8 | Product used for unknown indication |
| 126182961 | 12618296 | 9 | Product used for unknown indication |
| 126182961 | 12618296 | 10 | Product used for unknown indication |
| 126182961 | 12618296 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126182961 | 12618296 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126182961 | 12618296 | Agranulocytosis | |
| 126182961 | 12618296 | Leukopenia | |
| 126182961 | 12618296 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126182961 | 12618296 | 1 | 20160205 | 0 | ||
| 126182961 | 12618296 | 3 | 20160208 | 0 | ||
| 126182961 | 12618296 | 4 | 20160208 | 0 |